Heron Therapeutics (HRTX) News Today

Heron Therapeutics, Inc. (NASDAQ: HRTX) has a major proposed asset sale that may be driving investor interest, while its latest results showed weaker-than-expected revenue.

• Positive Sentiment: Heron agreed to sell substantially all of its assets to CorMedix in a deal reported at approximately $280 million, with $223 million upfront. The transaction could provide substantial proceeds, though it remains subject to completion. Asset purchase agreement details
• Neutral Sentiment: The sale would give CorMedix four products and broaden its reach in institutional care; the longer-term impact for Heron will depend on the transaction terms and its plans after transferring the assets. CorMedix acquisition overview
• Negative Sentiment: Third-quarter revenue fell 7.8% year over year to $35.3 million, below the $37.5 million analyst estimate. Heron’s loss of $0.03 per share matched consensus, however, and was narrower than the year-earlier loss of $0.05. Third-quarter 2026 results